SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q3 2025 vs. Q2 2025
How the institutions holding SAB Biotherapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 25 | 34 | +9 |
| Shares | 1.92M | 28.0M | +26.1M (+1,356.6%) |
| Value | $3.37M | $56.3M | +$53.0M (+1,571.7%) |
New holders (13)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vivo Capital, LLC | 11,420,000 | $23.0M | 1.85% |
| Ra Capital Management, L.P. | 4,401,500 | $8.85M | 0.11% |
| Commodore Capital LP | 4,401,500 | $8.85M | 0.43% |
| Woodline Partners LP | 2,850,881 | $5.73M | 0.03% |
| Sphera Funds Management Ltd. | 566,395 | $1.14M | 0.27% |
| HB Wealth Management, LLC | 307,500 | $618.1K | 0.00% |
| AWM Investment Company, Inc. | 200,000 | $402.0K | 0.04% |
| Virtu Financial LLC | 19,982 | $40.0K | 0.00% |
| Dimensional Fund Advisors LP | 15,781 | $31.7K | 0.00% |
| ADAR1 Capital Management, LLC | 15,000 | $30.1K | 0.00% |
| Goldman Sachs Group Inc | 11,221 | $22.6K | 0.00% |
| Caxton Corp | 10,935 | $22.0K | 0.10% |
| Citigroup Inc | 832 | $1.67K | 0.00% |
Sold out (4)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Citadel Advisors LLC | 17,095 | $29.9K |
| Creative Planning | 11,852 | $20.8K |
| Sachetta, LLC | 4,100 | $7.20K |
| Raymond James Financial Inc | 45 | $79 |